Mureidomycin A, a new inhibitor of bacterial peptidoglycan synthesis.
Mureidomycin A (MRD), a novel peptidylnucleoside antibiotic with antipseudomonal activity, inhibited not only peptidoglycan synthesis but also lipid-intermediate formation from UDP-N-acetylmuramyl (MurNAc)-pentapeptide and UDP-N-acetylglucosamine in an in vitro peptidoglycan-synthesizing system, using ether-treated cells of Pseudomonas aeruginosa. Both types of inhibition by MRD disappeared when UDP-MurNAc-pentapeptide was preincubated with ether-treated cells. Moreover, MRD completely inhibited lipid-intermediate I (undecaprenyl-p-p-MurNAc-pentapeptide) formation at a concentration below the MIC. From these results, it was concluded that the real target of MRD's action was translocase, which catalyzes lipid-intermediate I formation from UDP-MurNAc-pentapeptide and a lipid carrier.
Isono
F
F
Fermentation Research Laboratories, Sankyo Co. Ltd., Tokyo, Japan.
Inukai
M
M
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001409:Bacillus cereus / Q000187:drug effects; D001419:Bacteria / Q000187:drug effects / Q000378:metabolism*; D050356:Lipid Metabolism; D009705:Nucleosides / Q000494:pharmacology; D010455:Peptides / Q000494:pharmacology; D010457:Peptidoglycan / Q000096:biosynthesis*; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000378:metabolism; D013104:Spheroplasts / Q000187:drug effects / Q000378:metabolism
D000900:Anti-Bacterial Agents; D009705:Nucleosides; D010455:Peptides; D010457:Peptidoglycan; C059803:mureidomycin A